Seoul National University

Korea Research Institute of Standards and Science

Avixgen Inc.

Ewha University-industry Collaboration Foundation

Toolgen Inc.

Dong Hyun Jo

Jeong Hun Kim

Tae Geol Lee

Yi Yong Baek

Won Jin Park

Young Myeong Kim

Jung Min Lee

Soohyun Kim

Junho Chung

Hyori Kim

Dong Woo Song

Un Gi Kim

Ri Mi Lee

Suree Kim

Dongmin Kang

Dobeen Hwang

The present invention relates to an antibody against a PDGF receptor, an antibody-drug conjugate in which a chemotherapeutic agent is conjugated to the antibody against PDGF receptor, and a use of prevention or treatment of ocular neovascular diseases.

PDGF receptor antibody and use thereof

The present invention relates to a composition for gene manipulation for treating or improving a retinal dysfunction disease or a method using the same. More particularly, the present invention relates to a composition for gene manipulation including a guide nucleic acid capable of targeting a retinal function-forming gene and a method of treating or improving a disease caused by retinal dysfunction by artificially manipulating and/or correcting a retinal function-forming gene using the same.

Gene manipulation for treatment of retinal dysfunction disorder

Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.

Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient

Provided is a method for screening drugs, more particularly, a method for screening drugs by measuring capacitance of an endothelial cell layer at a frequency region of 100 Hz to 5 kHz to screen a drug affecting paracellular permeability of the endothelial cell layer or a drug penetrating through a paracellular path.

Method of screening drugs

Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.

Composition for inhibiting angiogenesis comprising nanoparticle-vitreous body-based protein complex as active ingredient, and use thereof

Provided is a pharmaceutical composition containing inorganic nanoparticles selected from titanium oxide nanoparticles or silica nanoparticles as an active ingredient for preventing or treating angiogenesis-related diseases. The pharmaceutical composition for preventing or treating angiogenesis-related diseases according to the present invention may be used as a therapeutic agent for various diseases based on angiogenesis such as age-related macular degeneration, tumors, and diabetes-related complications.

Composition containing inorganic nanoparticles as an active ingredient for preventing or treating of angiogenesis-related diseases

Growing community of inventors

Seoul, South Korea

Dong Hyun Jo